| Year |
Citation |
Score |
| 2022 |
Bourne CM, Mun SS, Dao T, Aretz ZEH, Molvi Z, Gejman RS, Daman A, Takata K, Steidl C, Klatt MG, Scheinberg DA. Unmasking the suppressed immunopeptidome of EZH2 mutated diffuse large B-cell lymphomas with combination drug treatment. Blood Advances. PMID 35561310 DOI: 10.1182/bloodadvances.2021006069 |
0.576 |
|
| 2020 |
Klatt MG, Aretz ZEH, Curcio M, Gejman RS, Jones HF, Scheinberg DA. An input-controlled model system for identification of MHC bound peptides enabling laboratory comparisons of immunopeptidome experiments. Journal of Proteomics. 103921. PMID 32758705 DOI: 10.1016/J.Jprot.2020.103921 |
0.523 |
|
| 2020 |
Gejman RS, Jones HF, Klatt MG, Chang AY, Oh CY, Chandran SS, Korontsvit T, Zakahleva V, Dao T, Klebanoff CA, Scheinberg DA. Identification of the targets of T cell receptor therapeutic agents and cells by use of a high throughput genetic platform. Cancer Immunology Research. PMID 32184297 DOI: 10.1158/2326-6066.Cir-19-0745 |
0.736 |
|
| 2019 |
Klatt MG, Gejman RS, Moon SS, Korontsvit TS, Dao T, Scheinberg DA. Abstract PR13: A new high-performance HLA ligand identification strategy enables prediction of T-cell tolerance to neoepitopes Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-Pr13 |
0.634 |
|
| 2018 |
Gejman RS, Chang AY, Jones HF, DiKun K, Hakimi AA, Schietinger A, Scheinberg DA. Rejection of immunogenic tumor clones is limited by clonal fraction. Elife. 7. PMID 30499773 DOI: 10.7554/Elife.41090 |
0.737 |
|
| 2018 |
Gejman RS, Chang AY, Jones HF, DiKun K, Hakimi AA, Schietinger A, Scheinberg DA. Author response: Rejection of immunogenic tumor clones is limited by clonal fraction Elife. DOI: 10.7554/Elife.41090.026 |
0.642 |
|
| 2018 |
Klatt M, Gejman R, Mun SS, Dao T, Scheinberg D. Improved Sensitivity and Specificity for Mutated and Unmutated Class I HLA Ligand Identifications Lead to Better Immunotherapy Target Discovery Clinical Lymphoma Myeloma and Leukemia. 18: S297. DOI: 10.1016/J.Clml.2018.07.247 |
0.557 |
|
| 2017 |
Chang AY, Dao T, Gejman RS, Jarvis CA, Scott A, Dubrovsky L, Mathias MD, Korontsvit T, Zakhaleva V, Curcio M, Hendrickson RC, Liu C, Scheinberg DA. A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens. The Journal of Clinical Investigation. 127: 3557. PMID 28862643 DOI: 10.1172/JCI96860 |
0.748 |
|
| 2017 |
Chang AY, Dao T, Gejman RS, Jarvis CA, Scott A, Dubrovsky L, Mathias MD, Korontsvit T, Zakhaleva V, Curcio M, Hendrickson RC, Liu C, Scheinberg DA. A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens. The Journal of Clinical Investigation. PMID 28628042 DOI: 10.1172/Jci92335 |
0.762 |
|
| 2017 |
Şenbabaoğlu Y, Gejman RS, Winer AG, Liu M, Van Allen EM, de Velasco G, Miao D, Ostrovnaya I, Drill E, Luna A, Weinhold N, Lee W, Manley BJ, Khalil DN, Kaffenberger SD, et al. Erratum to: Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biology. 18: 46. PMID 28249590 DOI: 10.1186/S13059-017-1180-8 |
0.547 |
|
| 2017 |
Gejman RS, Dao T, Scheinberg DA. Identification of Cross-Reactive Targets of TCR-Based Therapeutic Agents within the Human Proteome Blood. 130: 3188-3188. DOI: 10.1182/Blood.V130.Suppl_1.3188.3188 |
0.712 |
|
| 2016 |
Şenbabaoğlu Y, Gejman RS, Winer AG, Liu M, Van Allen EM, de Velasco G, Miao D, Ostrovnaya I, Drill E, Luna A, Weinhold N, Lee W, Manley BJ, Khalil DN, Kaffenberger SD, et al. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biology. 17: 231. PMID 27855702 DOI: 10.1186/S13059-016-1092-Z |
0.612 |
|
| 2016 |
Brea EJ, Oh CY, Manchado E, Budhu S, Gejman RS, Mo G, Mondello P, Han JE, Jarvis CA, Ulmert D, Xiang Q, Chang AY, Garippa RJ, Merghoub T, Wolchok JD, et al. Kinase regulation of Human MHC Class I Molecule Expression on Cancer Cells. Cancer Immunology Research. PMID 27680026 DOI: 10.1158/2326-6066.Cir-16-0177 |
0.729 |
|
| 2016 |
Y Chang A, Gejman R, J Brea E, Y Oh C, Mathias M, Pankov D, Casey E, Dao T, Scheinberg DA. Opportunities and challenges for TCR mimic antibodies in cancer therapy. Expert Opinion On Biological Therapy. PMID 27094818 DOI: 10.1080/14712598.2016.1176138 |
0.709 |
|
| 2016 |
Dubrovsky L, Dao T, Gejman RS, Brea EJ, Chang AY, Oh CY, Casey E, Pankov D, Scheinberg DA. T cell receptor mimic antibodies for cancer therapy. Oncoimmunology. 5: e1049803. PMID 26942058 DOI: 10.1080/2162402X.2015.1049803 |
0.75 |
|
| 2016 |
Winer AG, Senbabaoglu Y, Gejman R, Ostrovnaya I, Kaffenberger SD, Voss MH, Coleman JA, Russo P, Hsieh J, Sander C, Hakimi AA. The immune landscape of renal cell carcinoma and its association with intratumoral clonality. Journal of Clinical Oncology. 34: 605-605. DOI: 10.1200/Jco.2016.34.2_Suppl.605 |
0.483 |
|
| 2016 |
Brea EJ, Oh C, Manchado E, Gejman R, Mo G, Mondello P, Garippa R, Rosen N, Scheinberg DA. Abstract 4899: The regulation by kinases of the expression of human major histocompatibility class I molecules Cancer Research. 76: 4899-4899. DOI: 10.1158/1538-7445.Am2016-4899 |
0.609 |
|
| 2016 |
Dubrovsky L, Dao T, Gejman RS, Brea EJ, Chang AY, Oh CY, Casey E, Pankov D, Scheinberg DA. T cell receptor mimic antibodies for cancer therapy Oncoimmunology. 5. DOI: 10.1080/2162402X.2015.1049803 |
0.685 |
|
| Show low-probability matches. |